Nongoitrous (type I) amiodarone-associated thyrotoxicosis: Evidence of follicular disruption in vitro and in vivo

M. D. Brennan, D. Z. Erickson, J. A. Carney, R. S. Bahn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT). AAT occurs in patients both with and without preexisting goiter. In our study of the nongoitrous variety, the effect in vitro of amiodarone treatment and of concurrent treatment with potential inhibitors on thyroid cells (FRTL-5) was assessed by measuring the release of radiolabeled chromium (51Cr). In addition, thyroid histopathology was evaluated in autopsy specimens from six amiodarone-treated patients who had no pretreatment evidence of thyroid disease. Histopathologic examination revealed minimal or no evidence of thyroid follicular damage in specimens from amiodarone-treated euthyroid patients (n = 4). In contrast, moderate to severe follicular damage and disruption were present in glands from patients with AAT (n = 2). Studies in vitro showed amiodarone to be cytotoxic to thyroid cells; this effect was inhibited by treatment with dexamethasone (10-3 mmol) or perchlorate (2.5 μg/mL). In summary, we demonstrate evidence in vitro and in vivo of amiodarone-induced thyroid follicular damage and disruption in specimens from patients with nongoitrous AAT and in cultured normal thyroid cells. In addition, we demonstrate inhibition of this effect following treatment in vitro with dexamethasone or perchlorate. Our findings support the concept that nongoitrous (type I) AAT results from direct drug toxicity with disruption of thyroid follicles and subsequent release of preformed thyroid hormone.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalThyroid
Volume5
Issue number3
StatePublished - 1995

Fingerprint

Thyrotoxicosis
Amiodarone
Thyroid Gland
Thyroid Hormones
Dexamethasone
In Vitro Techniques
Therapeutics
Thyroid Diseases
Goiter
Chromium
Hyperthyroidism
Hypothyroidism
Drug-Related Side Effects and Adverse Reactions
Autopsy

ASJC Scopus subject areas

  • Endocrinology

Cite this

Brennan, M. D., Erickson, D. Z., Carney, J. A., & Bahn, R. S. (1995). Nongoitrous (type I) amiodarone-associated thyrotoxicosis: Evidence of follicular disruption in vitro and in vivo. Thyroid, 5(3), 177-183.

Nongoitrous (type I) amiodarone-associated thyrotoxicosis : Evidence of follicular disruption in vitro and in vivo. / Brennan, M. D.; Erickson, D. Z.; Carney, J. A.; Bahn, R. S.

In: Thyroid, Vol. 5, No. 3, 1995, p. 177-183.

Research output: Contribution to journalArticle

Brennan, MD, Erickson, DZ, Carney, JA & Bahn, RS 1995, 'Nongoitrous (type I) amiodarone-associated thyrotoxicosis: Evidence of follicular disruption in vitro and in vivo', Thyroid, vol. 5, no. 3, pp. 177-183.
Brennan, M. D. ; Erickson, D. Z. ; Carney, J. A. ; Bahn, R. S. / Nongoitrous (type I) amiodarone-associated thyrotoxicosis : Evidence of follicular disruption in vitro and in vivo. In: Thyroid. 1995 ; Vol. 5, No. 3. pp. 177-183.
@article{313a46501a524daab2537a1b94fda900,
title = "Nongoitrous (type I) amiodarone-associated thyrotoxicosis: Evidence of follicular disruption in vitro and in vivo",
abstract = "Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT). AAT occurs in patients both with and without preexisting goiter. In our study of the nongoitrous variety, the effect in vitro of amiodarone treatment and of concurrent treatment with potential inhibitors on thyroid cells (FRTL-5) was assessed by measuring the release of radiolabeled chromium (51Cr). In addition, thyroid histopathology was evaluated in autopsy specimens from six amiodarone-treated patients who had no pretreatment evidence of thyroid disease. Histopathologic examination revealed minimal or no evidence of thyroid follicular damage in specimens from amiodarone-treated euthyroid patients (n = 4). In contrast, moderate to severe follicular damage and disruption were present in glands from patients with AAT (n = 2). Studies in vitro showed amiodarone to be cytotoxic to thyroid cells; this effect was inhibited by treatment with dexamethasone (10-3 mmol) or perchlorate (2.5 μg/mL). In summary, we demonstrate evidence in vitro and in vivo of amiodarone-induced thyroid follicular damage and disruption in specimens from patients with nongoitrous AAT and in cultured normal thyroid cells. In addition, we demonstrate inhibition of this effect following treatment in vitro with dexamethasone or perchlorate. Our findings support the concept that nongoitrous (type I) AAT results from direct drug toxicity with disruption of thyroid follicles and subsequent release of preformed thyroid hormone.",
author = "Brennan, {M. D.} and Erickson, {D. Z.} and Carney, {J. A.} and Bahn, {R. S.}",
year = "1995",
language = "English (US)",
volume = "5",
pages = "177--183",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Nongoitrous (type I) amiodarone-associated thyrotoxicosis

T2 - Evidence of follicular disruption in vitro and in vivo

AU - Brennan, M. D.

AU - Erickson, D. Z.

AU - Carney, J. A.

AU - Bahn, R. S.

PY - 1995

Y1 - 1995

N2 - Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT). AAT occurs in patients both with and without preexisting goiter. In our study of the nongoitrous variety, the effect in vitro of amiodarone treatment and of concurrent treatment with potential inhibitors on thyroid cells (FRTL-5) was assessed by measuring the release of radiolabeled chromium (51Cr). In addition, thyroid histopathology was evaluated in autopsy specimens from six amiodarone-treated patients who had no pretreatment evidence of thyroid disease. Histopathologic examination revealed minimal or no evidence of thyroid follicular damage in specimens from amiodarone-treated euthyroid patients (n = 4). In contrast, moderate to severe follicular damage and disruption were present in glands from patients with AAT (n = 2). Studies in vitro showed amiodarone to be cytotoxic to thyroid cells; this effect was inhibited by treatment with dexamethasone (10-3 mmol) or perchlorate (2.5 μg/mL). In summary, we demonstrate evidence in vitro and in vivo of amiodarone-induced thyroid follicular damage and disruption in specimens from patients with nongoitrous AAT and in cultured normal thyroid cells. In addition, we demonstrate inhibition of this effect following treatment in vitro with dexamethasone or perchlorate. Our findings support the concept that nongoitrous (type I) AAT results from direct drug toxicity with disruption of thyroid follicles and subsequent release of preformed thyroid hormone.

AB - Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT). AAT occurs in patients both with and without preexisting goiter. In our study of the nongoitrous variety, the effect in vitro of amiodarone treatment and of concurrent treatment with potential inhibitors on thyroid cells (FRTL-5) was assessed by measuring the release of radiolabeled chromium (51Cr). In addition, thyroid histopathology was evaluated in autopsy specimens from six amiodarone-treated patients who had no pretreatment evidence of thyroid disease. Histopathologic examination revealed minimal or no evidence of thyroid follicular damage in specimens from amiodarone-treated euthyroid patients (n = 4). In contrast, moderate to severe follicular damage and disruption were present in glands from patients with AAT (n = 2). Studies in vitro showed amiodarone to be cytotoxic to thyroid cells; this effect was inhibited by treatment with dexamethasone (10-3 mmol) or perchlorate (2.5 μg/mL). In summary, we demonstrate evidence in vitro and in vivo of amiodarone-induced thyroid follicular damage and disruption in specimens from patients with nongoitrous AAT and in cultured normal thyroid cells. In addition, we demonstrate inhibition of this effect following treatment in vitro with dexamethasone or perchlorate. Our findings support the concept that nongoitrous (type I) AAT results from direct drug toxicity with disruption of thyroid follicles and subsequent release of preformed thyroid hormone.

UR - http://www.scopus.com/inward/record.url?scp=0029067954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029067954&partnerID=8YFLogxK

M3 - Article

C2 - 7580265

AN - SCOPUS:0029067954

VL - 5

SP - 177

EP - 183

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 3

ER -